Jack E. Pace
White & Case (New York)
Lawyer (Partner)
Mr. Pace is a member of White & Case’s Global Competition and Commercial Litigation Practice Groups. He concentrates on complex commercial litigation and counseling in the areas of antitrust and trade regulation. Mr. Pace has extensive experience defending companies in complex, multi-jurisdictional class actions, including those involving claims under the antitrust laws, consumer protection statutes and Title VII. Mr. Pace regularly represents clients in the pharmaceutical, financial services, agricultural and insurance industries. Mr. Pace is an Associate Editor of Antitrust Magazine and regularly publishes articles on antitrust law, class certification and other complex commercial litigation topics. Mr. Pace is a member of White & Case’s Knowledge and Technology Committee and has many years of experience advising clients on e-discovery issues such as document retention policies, document collection and discovery management. Mr. Pace is a member of the Board of Directors of Reach Out and Read of Greater New York, a not-for-profit organization focusing on pediatric literacy. He also serves as liaison in connection with the Firm’s work with inMotion, a not-for-profit organization that provides free legal and social services to low income women in New York City, and supervises the Firm’s pro bono special education cases.
Distinctions
Linked authors
Fanny Abouzeid
White & Case (Brussels)
Adam Acosta
White & Case (Washington)
Kevin Adam
White & Case (New York)
Allain Andry
White & Case (Washington)
Joseph Angland
White & Case (New York)
2168 | Conferences
Videos
Articles
2047 Bulletin
491
A new Executive Order signed by President Biden includes 72 initiatives instructing more than a dozen federal agencies, including the US Department of Justice and the Federal Trade Commission, to, according to the White House’s Fact Sheet, "promptly tackle some of the most pressing competition (...)
157
What’s next for drug pricing in the US? Proposals to alter antitrust and patent laws may signal a renewed focus on drug pricing by federal lawmakers, while the growing web of state laws is expected to increase compliance challenges for the pharmaceutical industry. What’s changing? A new (...)
204
For the thousands of financial institutions anxiously watching the discontinuation and transition from certain interbank offered rates (“IBORs”), 2020 just got a little less chaotic. On Thursday, October 1, 2020, the United States Department of Justice Antitrust Division issued its highly (...)
123
This article has been nominated for the 2020 Antitrust Writing Awards. Click here to learn more about the Antitrust Writing Awards. On October 7, 2019, California became the first state to enact legislation— Assembly Bill 824 (“AB 824”)—rendering certain pharmaceutical patent litigation settlement (...)
288
In a decision that may reverberate beyond the antitrust context, New York’s highest court - the Court of Appeals - held that the state’s antitrust statute lacks the extraterritorial scope to reach a purely foreign alleged antitrust conspiracy. The decision could have broad implications for (...)
342
According to published reports, the Antitrust Division of the US Department of Justice (DOJ) has opened an investigation into possible collusion among various hedge funds that trade euro contracts. The inquiry comes amid a sharp decline in the value of the euro, which has fallen approximately (...)
117
On May 11, 2009, the Antitrust Division of the Department of Justice (“DOJ”), in a speech by new Assistant Attorney General Christine A. Varney and a press release issued later in the day, formally withdrew the report entitled Competition and Monopoly: Single-Firm Conduct under Section 2 of the (...)
325
As any experienced litigator of complex civil cases can attest, clarifying (and potentially containing) the scope of discovery is a critical task. Regardless of the substantive law at issue, tremendous resources often are required to fulfill the duty to preserve and disclose relevant (...)
